论文部分内容阅读
目的:研究静脉注射用丙种球蛋白(IVγG)体内外抗呼吸道合胞病毒(RSV)的作用。方法:①采用微量细胞病变抑制法试验(MCIA),检测不同浓度的IVγG抑制RSV的作用。②建立RSV感染的BALB/c小鼠模型,将40只感染RSV的小鼠分为4组,即IVγG治疗组、病毒唑治疗组、Palivizumab治疗组、生理盐水对照组,及10只未感染RSV的小鼠作为正常对照组,每组10只。于治疗后第5及第7天,分2批处死小鼠,分离病毒并观察肺组织的病理积分。结果:①IVγG具有抑制RSV的作用,其治疗指数(TI)为275,较病毒唑高6倍,较Palivizumab低2倍。②IVγG治疗组小鼠肺组织的病理积分较生理盐水对照组明显减低(P<0.01),但其5d的治疗作用低于Palivizumab治疗组(P<0.05)。结论:IVγG在体内外均有一定的抗RSV的作用,但效果均低于Palivizumab。
Objective: To study the effect of intravenous immunoglobulin (IVγG) against respiratory syncytial virus (RSV) in vitro and in vivo. Methods: ①Microcellocytosis inhibition test (MCIA) was used to detect the effect of different concentrations of IVγG on RSV. ② To establish a BALB / c mouse model of RSV infection, 40 mice infected with RSV were divided into 4 groups: IVγG treatment group, Ribavirin treatment group, Palivizumab treatment group, saline control group and 10 non-infected RSV Of mice as normal control group, 10 mice in each group. On the 5th and 7th day after treatment, the mice were killed in 2 batches, the virus was separated and the pathological score of the lung tissue was observed. Results: ①IVγG has the effect of inhibiting RSV, its therapeutic index (TI) is 275, 6 times higher than ribavirin, and 2 times lower than Palivizumab. ② The pathological score of lung tissue inIVγG treatment group was significantly lower than that of saline control group (P <0.01), but the therapeutic effect of 5 Gy was lower than that of Palivizumab treatment group (P <0.05). Conclusion: IVγG has anti-RSV effect both in vitro and in vivo, but the effect is lower than that of Palivizumab.